|
PATHWAY MEDICAL TECHNOLOGIES SEES 172% GROWTH OVER LAST 2 QUARTERS WITH JETSTREAM REVASCULARIZATION CATHETER Company Achieves Significant Milestone for First Single Device Capable of Treating Entire Spectrum of Peripheral Arterial Disease, Technology to be Showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2009 KIRKLAND, Wash. and SAN FRANCISCO––Transcatheter Cardiovascular Therapeutics (TCT) 2009, Booth #800—September 22, 2009––Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States. This significant company milestone comes on the heels of Pathway’s recent launch of the Jetstream G2™ NXT, a 7 French compatible version of its peripheral revascularization catheter. Pathway’s transformational technology will be on display at TCT 2009, taking place September 21-25, 2009 at the Moscone Center in San Francisco. “The number of patients in the U.S. afflicted with PAD is expected to grow exponentially over the next 10 years,” said Pathway Medical Technologies President and CEO Paul Buckman. “Our newest products, including Jetstream G2 NXT with 7 French compatibility, demonstrate our continued commitment to delivering best-in-class revascularization solutions for the PVD market. The fact that physicians and patients alike are embracing Jetstream as an effective, first-line treatment option to remove all types of hard and soft tissue plaque underscores its clinical utility and versatility. We are excited about the momentum achieved in the past 12 months and look forward to securing our place as the leader in PVD innovations in the months to come.” Jetstream G2 NXT is based on Pathway’s state-of-the-art catheter technology capable of treating the entire spectrum of disease found in patients suffering from PVD, including calcium, soft plaque, fibrotic lesions and thrombus. 7 French compatibility allows physicians to use Jetstream G2 NXT in the treatment of PVD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology.
Pathway Medical Technologies, Inc. will exhibit at TCT 2009 in booth #800. Media interested in meeting with Pathway at the conference should contact Marisa Borgasano or Rebecca Phillips at Schwartz Communications, (415) 512-0770 or PathwayMedical@schwartz-pr.com. About Jetstream G2 NXT Jetstream G2 NXT consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has an expandable cutting tip that safely debulks and preemptively removes calcium and soft plaque, as well as fibrotic lesions and thrombus. A highly efficient aspiration port located just proximal to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization. With simple set up and an ergonomic design for easy operation by trained clinicians, Jetstream G2 NXT maximizes treatment effectiveness and offers renewed hope for non-surgical candidates and the benefits of a minimally invasive treatment option, including faster recovery and decreased systemic complications. About Pathway Medical Technologies, Inc. * * * Media Contact: |
|
